A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy

High-grade neuroendocrine carcinoma differs from usual neuroendocrine carcinoma, and its prognosis is dismal. In this case report, a case of high-grade neuroendocrine carcinoma that improved with bevacizumab plus modified FOLFOX6 as the fourth-line chemotherapy is presented. A 29-year-old male with...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Satoshi, Honma, Rio, Taguchi, Jun, Amano, Toraji, Shimizu, Yasushi, Kinoshita, Ichiro, Kubota, Kanako, Matsuno, Yoshihiro, Dosaka-Akita, Hirotoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Published: May 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124459/
https://www.ncbi.nlm.nih.gov/pubmed/21734880
http://dx.doi.org/10.1159/000328802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124459/
https://www.ncbi.nlm.nih.gov/pubmed/21734880
http://dx.doi.org/10.1159/000328802

Ejemplares similares